309 related articles for article (PubMed ID: 34344467)
1. Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies.
Ramos-Kuri M; Meka SH; Salamanca-Buentello F; Hajjar RJ; Lipskaia L; Chemaly ER
Biol Res; 2021 Aug; 54(1):23. PubMed ID: 34344467
[TBL] [Abstract][Full Text] [Related]
2. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
3. Objective studies of the face of Noonan, Cardio-facio-cutaneous, and Costello syndromes: A comparison of three disorders of the Ras/MAPK signaling pathway.
Allanson JE
Am J Med Genet A; 2016 Oct; 170(10):2570-7. PubMed ID: 27155212
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
Molkentin JD
Cardiovasc Res; 2004 Aug; 63(3):467-75. PubMed ID: 15276472
[TBL] [Abstract][Full Text] [Related]
6. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
7. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
[TBL] [Abstract][Full Text] [Related]
8. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro.
Aoki H; Richmond M; Izumo S; Sadoshima J
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):275-84. PubMed ID: 10727428
[TBL] [Abstract][Full Text] [Related]
9. RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
Cuevas-Navarro A; Wagner M; Van R; Swain M; Mo S; Columbus J; Allison MR; Cheng A; Messing S; Turbyville TJ; Simanshu DK; Sale MJ; McCormick F; Stephen AG; Castel P
Sci Adv; 2023 Jul; 9(28):eadf4766. PubMed ID: 37450595
[TBL] [Abstract][Full Text] [Related]
10. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways.
De Windt LJ; Lim HW; Haq S; Force T; Molkentin JD
J Biol Chem; 2000 May; 275(18):13571-9. PubMed ID: 10788473
[TBL] [Abstract][Full Text] [Related]
12. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
Zenker M
Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
[TBL] [Abstract][Full Text] [Related]
14. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload.
Harris IS; Zhang S; Treskov I; Kovacs A; Weinheimer C; Muslin AJ
Circulation; 2004 Aug; 110(6):718-23. PubMed ID: 15289381
[TBL] [Abstract][Full Text] [Related]
15. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
16. Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases.
Kometiani P; Li J; Gnudi L; Kahn BB; Askari A; Xie Z
J Biol Chem; 1998 Jun; 273(24):15249-56. PubMed ID: 9614140
[TBL] [Abstract][Full Text] [Related]
17. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
[TBL] [Abstract][Full Text] [Related]
19. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells.
Shin I; Kim S; Song H; Kim HR; Moon A
J Biol Chem; 2005 Apr; 280(15):14675-83. PubMed ID: 15677464
[TBL] [Abstract][Full Text] [Related]
20. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
